https://dxm-atlas.org/en/interactions/selegiline-rasagiline-safinamide-selectivity-maintained/
CompareWhy is there no PHI rating?
Full explanation from the review
Selegiline, rasagiline, and safinamide with maintained MAO-B selectivity are excluded from numerical ranking. Contraindications remain relevant, but evidence is insufficient to quantify physiological concern under that specific condition [26, 34, 44]. Datura and Atropa belladonna are excluded because variable alkaloid concentrations undermine the known-exposure assumption [35]. Ondansetron is excluded because of its disputed serotonergic mechanism and insufficient assessment of the pure pair; QT-prolonging drugs are excluded as a class because mechanisms and conditions vary [4, 30, 31]. Their concerns are discussed in Sections 5 and 8.
General concepts in this text
MAO-B
A form of the MAO enzyme involved in breaking down some chemical messengers in the monoamine group.
MAO-A and MAO-B are two different forms of monoamine oxidase. The letter B identifies the enzyme form.
Sources: MAO-B
- Edmondson, Binda, Mattevi: Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B · Arch Biochem Biophys. 2007;464(2):269–276; DOI 10.1016/j.abb.2007.05.006; PMID 17573034
MAO-B selectivity
Preferential inhibition of the MAO-B form of the enzyme compared with MAO-A.
MAO-A and MAO-B are two forms of monoamine oxidase. Loss of selectivity means more pronounced inhibition of MAO-A.
Sources: MAO-B selectivity
- Merck Manual Professional: Drug–Receptor Interactions — selectivity · Full review June 2025; Abimbola Farinde; peer reviewed by Eva M. Vivian
- EMSAM U.S. prescribing information — MAO isoenzymes and selectivity · U.S. prescribing information revised May 2020; section 12.2
Sources
- [26] RASAGILINE prescribing information · Open publication
- [34] ZELAPAR selegiline prescribing information · Open publication
- [44] XADAGO (safinamide) prescribing information · Open publication